| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2022-07-20 |
| タイトル |
|
|
タイトル |
A Retrospective Cohort Study Comparing Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
esophageal squamous cell carcinoma |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
prognosis |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
neoadjuvant treatment |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
chemoradiotherapy |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
esophagectomy |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.20569/00006058 |
|
ID登録タイプ |
JaLC |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 作成者 |
Sato, Yusuke
Motoyama, Satoru
Maeda, Eri
Wada, Yuki
Wakita, Akiyuki
Nagaki, Yushi
Fujita, Hiromu
Kemuriyama, Kohei
Hayashi, Kenjiro
Nomura, Kyoko
Minamiya, Yoshihiro
|
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background : Based on results from the Japan Clinical Oncology Group (JCOG) 9204 and JCOG 9907 trials, neoadjuvant-CF (cisplatin+5-fluorouracil) followed by esophagectomy with extended lymphadenectomy is the standard treatment for patients with locally advanced thoracic esophageal squamous cell carcinoma (ESCC) in Japan. Recently, however, results from the JCOG 1109 trial revealed that neoadjuvant-DCF (docetaxel+cisplatin+5-fluorouracil) provides significantly better overall survival (OS) than neoadjuvant-CF, whereas neoadjuvant chemoradiotherapy (NACRT) did not produce significantly better outcomes than neoadjuvant-CF.
Methods : We retrospectively identified 225 ESCC patients treated between December 2008 and December 2021 who received esophagectomy at Akita University Hospital. These patients were divided into neoadjuvant-CF (NAC, n=30) and NACRT (NACRT, n=195) groups before esophagectomy. Using the Kaplan-Meier method, we compared OS and disease-specific survival (DSS) between the two groups.
Results : The pathological response to treatment was significantly better in the NACRT than the NAC group. Although 5-year OS and DSS were better in the NACRT than NAC group, these differences did not reach statistical significance.
Conclusion : Among patients with locally advanced thoracic ESCC, NACRT produced a significantly better pathological response than NAC. However, NACRT did not produce significantly better long-term survival than NAC, which is consistent with the results of JCOG 1109. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 書誌情報 |
ja : 秋田医学
en : Akita journal of medicine
巻 49,
号 1,
p. 53-63,
発行日 2022-06-30
|
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0386-6106 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AN00009294 |
| 出版者 |
|
|
出版者 |
秋田医学会 |
akitai49_1(53).pdf (654.9 kB)
